MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, September 28, 2015

New MS Drug To Be Distributed By Global Supply Chain Distributor Durbin

New MS Drug To Be Distributed By Global Supply Chain Distributor Durbin

Medical Need Europe, a privately held pharmaceutical company headquartered in Sweden and focused on registration, distribution, marketing and sale of orphan drugs and niche speciality pharmaceuticals for treatment of rare diseases, has appointed London, U.K. based Durbin PLC, a leading global supplier and distributor of pharmaceuticals, to manage warehousing and supply chain for a range of Medical Need products.
At the outset, this collaboration will involve a single product, Medical Need’s progressive multiple sclerosis (MS) management drug MD1003, which is currently under clinical development.
In April, Medical Need partner MedDay Pharmaceuticals, a biotechnology company focused on treatment of nervous system disorders, founded in 2011 by neurologist and neuroscientist Fredric Sedel, MD, PhD, and Guillaume Brion, announced positive results from the pivotal randomized 2:1, double-blinded, placebo-controlled Phase III clinical trial MS-SPI. The trial was conducted in 16 MS reference centers in France, and showed evidence of the efficacy and safety of MD1003, a highly concentrated pharmaceutical-grade biotin administered at a dose of 300 mg per day for treatment of primary and secondary progressive multiple sclerosis, a major area of unmet medical need. Treatment duration was one year.
The company reported that the MS-SPI clinical trial’s primary endpoint was met with a proportion of MS patients showing an improvement in EDSS (expanded disability status scale) or TW25 (timed 25-foot walk) at Month 9 and confirmed at Month 12 (p = 0.0051). The primary endpoint was supported by evidence of a substantial decrease in the risk of disease progression.
The patient population was defined as patients suffering from primary progressive Multiple Sclerosis (PPMS) or secondary progressive Multiple Sclerosis (SPMS) with EDSS progression within the two years prior to inclusion, and with EDSS ranging from 4.5 to 7. Patients with disease modifying therapy (DMT) introduced less than 3 months prior to inclusion; fampridine introduced less than 1 month prior to inclusion; or evidence of relapse or Gadolinium-MRI activity within the past year were excluded from the study.

MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here

No comments: